MYO logo

Myomo, Inc. Stock Price

NYSEAM:MYO Community·US$35.1m Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 35 Fair Values set on narratives written by author

MYO Share Price Performance

US$0.90
-5.19 (-85.21%)
US$2.00
Fair Value
US$0.90
-5.19 (-85.21%)
55.0% undervalued intrinsic discount
US$2.00
Fair Value
Price US$0.90
AnalystLowTarget US$2.00

MYO Community Narratives

AnalystLowTarget·
Fair Value US$2 55.0% undervalued intrinsic discount

Medicare Access And Margin Pressures Will Dominate Before Long-Term Rehabilitation Demand Emerges

1users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$2
55.0% undervalued intrinsic discount
Revenue
15.4% p.a.
Profit Margin
12.91%
Future PE
14.5x
Price in 2028
US$2.23

Trending Discussion

Updated Narratives

MYO logo

Medicare Access And Margin Pressures Will Dominate Before Long-Term Rehabilitation Demand Emerges

Fair Value: US$2 55.0% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Excellent balance sheet with reasonable growth potential.

3 Risks
2 Rewards

Myomo, Inc. Key Details

US$41.6m

Revenue

US$13.9m

Cost of Revenue

US$27.7m

Gross Profit

US$39.7m

Other Expenses

-US$12.0m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-0.31
66.56%
-28.86%
27.3%
View Full Analysis

About MYO

Founded
2004
Employees
185
CEO
Paul Gudonis
WebsiteView website
myomo.com

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the brace; and MyoPro2+, which comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, the veteran’s administration, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Burlington, Massachusetts.

Recent MYO News & Updates

Recent updates

No updates